Literature DB >> 14985161

A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation.

R C Barfield1, M Otto, J Houston, M Holladay, T Geiger, J Martin, T Leimig, P Gordon, X Chen, R Handgretinger.   

Abstract

BACKGROUND: The presence of T and B cells in allogeneic grafts contributes to GvHD and to EBV-associated lymphoproliferative disease (LPD). Depletion of T and B cells from the graft decreases the risk of these complications.
METHODS: T and B cells were depleted from mobilized peripheral stem cells from volunteer donors (n=5) using anti-CD3 and anti-CD19 Abs conjugated to magnetic microbeads, and the CliniMACS device. The function of the stem cells after depletion was evaluated using colony assays and non-obese diabetic (NOD)/SCID repopulating experiments.
RESULTS: The mean mononuclear cell (MNC) count prior to T- and B-cell depletion was 2.19x10(10) (range 1.48-3.53). After depletion, the mean percentage of contaminating T cells was 0.02% (range 0.01-0.04%) with a mean log(10) depletion of 3.4 (range 3-3.8). The mean percentage of contaminating B cells was 0.1% (range 0.01-0.4%) with a mean log(10) depletion of 2.2 (range 1.4-3). The mean recovery of CD3- and CD19-negative MNCs after depletion was 70% (range 54-88%) and the mean recovery of CD34(+) stem cells was 69% (range 52-98%). The mean number of natural killer (NK) cells after T- and B-cell depletion was 5.2x10(8) (range 2-10x10(8)). In vitro colony assays and in vivo NOD/SCID repopulation assays showed no negative impact of this method on the function of the hematopoietic stem cells. DISCUSSION: Our results show that the CliniMACS system can be used to efficiently deplete PBSC of T and B cells simultaneously, without adverse effect on the graft.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985161     DOI: 10.1080/14653240310004411

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  15 in total

Review 1.  Overview of T-cell depletion in haploidentical stem cell transplantation.

Authors:  Nicola Daniele; Maria Cristina Scerpa; Maurizio Caniglia; Chiara Ciammetti; Cecilia Rossi; Maria Ester Bernardo; Franco Locatelli; Giancarlo Isacchi; Francesco Zinno
Journal:  Blood Transfus       Date:  2012-01-24       Impact factor: 3.443

2.  A novel high throughput immunomagnetic cell sorting system for potential clinical scale depletion of T cells for allogeneic stem cell transplantation.

Authors:  Xiaodong Tong; Ying Xiong; Maciej Zborowski; Sherif S Farag; Jeffrey J Chalmers
Journal:  Exp Hematol       Date:  2007-08-13       Impact factor: 3.084

Review 3.  Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.

Authors:  H J Symons; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-08-04       Impact factor: 5.483

Review 4.  Perspective on the role of haploidentical transplantation in the management of hematologic malignancies: why do it?

Authors:  Gregory A Hale
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

5.  Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study.

Authors:  Birgit Federmann; Martin Bornhauser; Christoph Meisner; Lambros Kordelas; Dietrich W Beelen; Gernot Stuhler; Matthias Stelljes; Rainer Schwerdtfeger; Maximilian Christopeit; Gerhard Behre; Christoph Faul; Wichard Vogel; Michael Schumm; Rupert Handgretinger; Lothar Kanz; Wolfgang A Bethge
Journal:  Haematologica       Date:  2012-04-04       Impact factor: 9.941

Review 6.  Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: a review.

Authors:  Liang-Piu Koh; Nelson J Chao
Journal:  Blood Cells Mol Dis       Date:  2007-09-19       Impact factor: 3.039

7.  Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation.

Authors:  Marcelo C Pasquini; Steven Devine; Adam Mendizabal; Lindsey R Baden; John R Wingard; Hillard M Lazarus; Frederick R Appelbaum; Carolyn A Keever-Taylor; Mary M Horowitz; Shelly Carter; Richard J O'Reilly; Robert J Soiffer
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

8.  Immunologic recovery in children after alternative donor allogeneic transplantation for hematologic malignancies: comparison of recipients of partially T cell-depleted peripheral blood stem cells and umbilical cord blood.

Authors:  Benjamin R Oshrine; Yimei Li; David T Teachey; Jennifer Heimall; David M Barrett; Nancy Bunin
Journal:  Biol Blood Marrow Transplant       Date:  2013-08-11       Impact factor: 5.742

Review 9.  Recent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescents.

Authors:  Ho Joon Im; Kyung-Nam Koh; Jong Jin Seo
Journal:  Blood Res       Date:  2016-03-25

10.  Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies.

Authors:  David F Stroncek; Vicki Fellowes; Chauha Pham; Hanh Khuu; Daniel H Fowler; Lauren V Wood; Marianna Sabatino
Journal:  J Transl Med       Date:  2014-09-17       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.